NCT00275431 2011-06-29Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell MalignanciesAscenta TherapeuticsPhase 2 Completed50 enrolled
NCT00440388 2010-08-27Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's LymphomaAscenta TherapeuticsPhase 2 Completed23 enrolled